Update of antispike severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) monoclonal antibodies (Record no. 18273)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | a |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | OSt |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20221118113328.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 221118b xxu||||| |||| 00| 0 eng d |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | AIKTC-KRRC |
| Transcribing agency | AIKTC-KRRC |
| 100 ## - MAIN ENTRY--PERSONAL NAME | |
| 9 (RLIN) | 19140 |
| Author | Chatterjee, Suparna |
| 245 ## - TITLE STATEMENT | |
| Title | Update of antispike severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) monoclonal antibodies |
| 250 ## - EDITION STATEMENT | |
| Volume, Issue number | Vol.54(1), Jan-Feb |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Place of publication, distribution, etc. | Mumbai |
| Name of publisher, distributor, etc. | Wolter Kluwer |
| Year | 2022 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Pagination | 51-57p. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | The use of monoclonal antibodies has expanded beyond the realm of autoimmune disease and cancer<br/>therapeutics to communicable diseases. Their antiviral activities were evaluated in some diseases<br/>such as SARS MERS (Middle East Respiratory Syndrome) and Ebola. In recent times, antispike<br/>SARS‑CoV‑2 monoclonal antibody cocktails (casirivimab with imdevimab and bamlanivimab with<br/>etesevimab) and single agent sotrovimab have received emergency use authorization for treatment of<br/>nonhospitalized COVID‑19 patients with mild‑to‑moderate disease at high risk of disease progression.<br/>This review summarizes their mechanism of action, salient pharmacokinetic profile, safety and clinical<br/>trial (ongoing and completed) data. Despite evidence to support its use for the indication, the high<br/>cost of these biologics may make it unaffordable for many patients, but further clinical studies on<br/>their cost‑benefit profile shall provide useful information to the scientific community and patients. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| 9 (RLIN) | 4774 |
| Topical term or geographic name entry element | PHARMACOLOGY |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| 9 (RLIN) | 19141 |
| Co-Author | Choudhury, Shouvik |
| 773 0# - HOST ITEM ENTRY | |
| Place, publisher, and date of publication | Andheri - Mumbai Wolters Kluwer India Private Limited |
| International Standard Serial Number | 0253-7613 |
| Title | Indian Journal of Pharmacology |
| 856 ## - ELECTRONIC LOCATION AND ACCESS | |
| URL | https://www.ijp-online.com/temp/IndianJPharmacol54151-2105218_055052.pdf |
| Link text | Click here |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Source of classification or shelving scheme | Dewey Decimal Classification |
| Koha item type | Articles Abstract Database |
| Withdrawn status | Lost status | Source of classification or shelving scheme | Damaged status | Not for loan | Home library | Current library | Shelving location | Date acquired | Total Checkouts | Barcode | Date last seen | Price effective from | Koha item type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dewey Decimal Classification | School of Pharmacy | School of Pharmacy | Archieval Section | 18/11/2022 | 2022-2152 | 18/11/2022 | 18/11/2022 | Articles Abstract Database |